印度监管机构由于安全问题,加强对GLP-1减肥药物的监督. Indian regulators tighten oversight of GLP-1 weight-loss drugs due to safety concerns.

印度正在增加对减肥和糖尿病药物的监督, 这种药物被称为GLP-1受体激动剂, 因为安全问题以及便宜的通用版本. India is increasing oversight of weight-loss and diabetes drugs, known as GLP-1 receptor agonists, due to safety concerns and the availability of cheaper generic versions. 政府正在检查卖家和诊所, 警告只有合格的医生才能开这些药. The government is inspecting sellers and clinics, warning that only qualified doctors can prescribe these medications. 当局还加强安全监测, 以追踪胰腺炎和损伤等副作用. Authorities are also strengthening safety monitoring to track side effects like pancreatitis and kidney injury.